华东医药：瑞玛比嗪注射液将由公司全资子公司中美华东在中国自主生产和销售

Core Viewpoint - The company is actively working on transferring the production of its renal filtration system and related drugs to domestic markets, with ongoing orders and preparations in place for both medical devices and pharmaceuticals [1] Group 1: Medical Devices - The company has received procurement orders for the transcutaneous glomerular filtration rate measurement device (TGFR) from various distributors and medical institutions for research and clinical use [1] - The company has completed inventory preparations with partners in advance for the TGFR device and is planning to transfer production to domestic facilities [1] Group 2: Pharmaceuticals - The company's wholly-owned subsidiary, China-US East, will independently produce and sell the drug Remabizine injection in China [1] - China-US East will also serve as one of the suppliers for MediBeacon in the U.S. market [1]